Loading cancer entity…
Loading cancer entity…
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03655223 | Early Check: Expanded Screening in Newborns | active not recruiting | — | 30,000 | RTI InternationalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01793168 | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford(CoRDS) | recruiting | — | 20,000 | Sanford HealthOTHER | 2 | May 29, 2025 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT00514046 |
Data updated 22 days agoSource updated Jul 1, 2026source: clinicaltrials
| completed |
| Phase 1 / Phase 2 |
| 17 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Dec 22, 2020 |
| clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |